Avadel Pharmaceuticals (AVDL) Change in Acquisitions & Divestments: 2015-2022
Historic Change in Acquisitions & Divestments for Avadel Pharmaceuticals (AVDL) over the last 8 years, with Dec 2022 value amounting to $24.0 million.
- Avadel Pharmaceuticals' Change in Acquisitions & Divestments rose 29.50% to $24.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $83.8 million, marking a year-over-year decrease of 18.00%. This contributed to the annual value of $327.8 million for FY2024, which is 75.16% up from last year.
- Per Avadel Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $24.0 million for Q4 2022, which was up 610.41% from $3.4 million recorded in Q3 2022.
- Avadel Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $194.4 million during Q1 2018, with a 5-year trough of $928,000 in Q2 2020.
- Its 3-year average for Change in Acquisitions & Divestments is $18.5 million, with a median of $16.2 million in 2020.
- Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first plummeted by 94.65% in 2020, then skyrocketed by 2,645.37% in 2021.
- Avadel Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $51.5 million in 2018, then tumbled by 88.34% to $6.0 million in 2019, then grew by 3.41% to $6.2 million in 2020, then spiked by 197.92% to $18.5 million in 2021, then grew by 29.50% to $24.0 million in 2022.
- Its Change in Acquisitions & Divestments stands at $24.0 million for Q4 2022, versus $3.4 million for Q3 2022 and $12.2 million for Q2 2022.